drugset / Trial / NCT03879863

The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

NCT03879863

Phase 3 Completed 422 enrolled Aldeyra Therapeutics, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The RENEW Trial is a Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap 0.25% Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease

Timeline

Start
2019-04-16
Primary completion
2019-10-04
Completion
2019-10-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Reproxalap Other / unclassified 0.25 %

Indications